Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Achillion doses first subject in Phase I trial of ACH-5228

Factor D protein from a human. Credit: Jmol Development Team.

  • Achillion Pharmaceuticals

Go Top